Jane Street’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Jane Street’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,838	Closed	-$970	–	10011
2023 Q1	$970	Sell	26,838 -380	-1%	-$26	﹤0.01%	8883
2022 Q4	$1.51K	Buy	27,218 +405	+2%	+$14	﹤0.01%	8947
2022 Q3	$1K	Sell	26,813 -857	-3%	-$54	﹤0.01%	9571
2022 Q2	$2K	Buy	27,670 +1,059	+4%	+$170	﹤0.01%	9490
2022 Q1	$5K	Buy	26,611 +11	+0%	+$4	﹤0.01%	10136
2021 Q4	$15K	Sell	26,600 -40	-0.2%	-$29	﹤0.01%	9857
2021 Q3	$19K	Buy	26,640 +40	+0.2%	+$34	﹤0.01%	9752
2021 Q2	$28K	Hold	26,600	–	–	﹤0.01%	9611
2021 Q1	$33K	Buy	+26,600	New	+$43.1K	﹤0.01%	8915

Jane Street's EUCRW Position: Q2 2023 in Review

Jane Street sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 26,838 shares — an estimated $970 sold.

Jane Street first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $33K in Q1 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Jane Street reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Jane Street sold 26,838 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $970.
Jane Street first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
Jane Street's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $33K in Q1 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.